We explored the feasibility of designing retroviral vectors that can target human breast cancer cells with characteristic receptors via ligand-receptor interaction. The
As gene delivery vehicles, retroviral vectors have been used extensively in clinical trials, including those for gene therapy of cancer. Retroviral vectors commonly used for gene transfer are derived from Moloney murine leukemia virus (Mo-MLV) and are classified as ecotropic or amphotropic according to their species specificity. The former only infects mouse cells, while the latter infects most mammalian cells, including human cells (1) . The ecotropic virus attaches to mouse cells via a binding interaction between the ecotropic envelope and a ubiquitous cationic amino acid transporter on the mouse cell surface. It does not infect human cells (2) presumably because the sequence of this amino acid transporter is divergent between murine and nonmurine species. The amphotropic virus enters mammalian cells by interacting with a phosphate transporter on the host cell surface that is also ubiquitous (3, 4) and highly conserved across different species, and hence it can infect mammalian cells of many species. Although these vectors thus show species specificity, within a given species neither vector exhibits tissue specificity because of the widespread distribution of amino acid transporters and phosphate transporters among various tissue types. Recently, Kasahara et al. (5) devised a strategy that alters retroviral host range by introducing modifications into the envelope of an ecotropic retrovirus. A peptide ligand was engineered into the envelope, and viruses pseudotyped with this modified envelope showed enhanced infection of murine cells expressing the receptor for that ligand. Furthermore, the ecotropic retrovirus bearing the human ligand could cross species and infect human cells bearing the appropriate receptors. Other studies have also shown that modifications of the retrovirus envelope could alter viral binding activity or tropism (6) (7) (8) . In this paper we describe the application of this strategy to the targeting of human breast cancer cells via the peptide ligand heregulin.
About 20% of breast cancer cells overexpress HER-2 [human epidermal growth factor (EGF) receptor; also called ERBB2] (9) . Two other members of the human epidermal growth factor receptor family, HER-3 and HER-4 (also called ERBB3 and ERBB4), have also been identified (10, 11) (12) . These are found in normal tissues such as breast, prostate, brain, skeletal muscle, ovary, testis, and small intestine. Heregulin is also expressed in many tissues as other isoforms, such as glial growth factors and acetylcholine receptor-inducing activity (13, 14) . The neu differentiation factor is the rat homologue of human heregulin (15) . The (Perkin-Elmer) , and H20 to a final volume of 50 pul; this PCR mixture was heated at 94°C for 2 min, followed by 30 cycles of heating at 94°C for 1 min, annealing at 66°C for 1 min, and elongation at 72°C for 2 min. For PCR of both a and 31 isoforms of heregulin, including amino acid residues between 35 and 239 (which contains both the immunoglobulin-like and EGF-like domains), 5'-GAGGTAACCTTGCCTCCCCAAT-TGAAAGAGATGAAAAGCCAG-3' was used as a common 5' primer in combination with isoform-specific 3' primers. For a heregulin, the sequence of the specific 3' primer used was 5'-TCGGATCCCGTACAGCrGCTCCGCCTTTTCrTGGT-TTTGGAC-3', and for (31 heregulin, the sequence of the specific 3' primer used was 5'-TCGGATCCCCTCCATAAATTCAA-TCCCAAGATGCTTGTAGAA-3' (the underlined nucleotides denote sequences added to generate restriction sites for cloning). Heregulin-gp70 chimeric envelope gene expression vectors were constructed by substitution of the Mo-MLV env gene between unique restriction sites BstEII (position 5923) and BamHI (position 6537) with a or (31 isoforms of heregulin cDNA. As mentioned above, BstEII and BamHI sites were generated by PCR-mediated site-directed mutagenesis on the 5' and 3' ends of the 615-bp a or (31 heregulin cDNA fragments encoding amino acid residues between 35 and 239, which contain both the immunoglobulin-like and EGF-like domains.
Rapid Testing of Vectors Expressing Heregulin-gp7O Chimeric Envelope Genes. The a or (31 heregulin-gp7O chimeric envelope genes were first transiently transfected into the ecotropic producer cell line +i-2/BAG by calcium phosphate precipitation (GIBCO/BRL). The ecotropic retrovirus thus transiently pseudotyped was harvested 48 hr later and tested for infectivity on MDA-MB-453 and MCF-7 cells. Infection of these human breast cancer cells was assayed by 5-bromo-4-chloro-3-indolyl 13-D-galactoside (X-Gal) staining (see below).
Establishment and Identification of Heregulin-gp7O Packaging Cell Lines. Vectors expressing the a or (31 heregulingp7O chimeric envelope genes and the hygromycin-resistance gene were cotransfected into qi-2 packaging cells by using the calcium phosphate precipitation method. The medium was changed 24 hr later, and 3 days after transfection, the selection was begun with Dulbecco's modified Eagle's medium (DMEM) containing 100 ,ug of hygromycin per ml; the medium was changed every 3 days thereafter. After selection for 20 days, hygromycin-resistant cell colonies formed and were picked for expansion and screening of cell lines that express the heregulin-gp7O chimeric envelope gene products. For identification of positive cell lines, cytoplasmic RNA was isolated from hygromycin-resistant colonies, and RT-PCR was performed as described above, using the same common heregulin 5' primer as that used in cloning and a 3' primer sequence derived from the Mo-MLV env gene, 5'-GAGTGGCTGTT-GGTCTGCCAGAAC-3'. The RT mix without addition of reverse transcriptase was used as a negative control. The plasmid DNAs encoding the heregulin-gp7O chimeric envelope genes were used as positive controls.
Production of Replication-Defective Retroviral Vectors and Infection of Target Cells. For transient production of replication-defective retroviral vectors, the plasmids pCRIP-SVlac and pBAG were transfected by calcium phosphate precipitation into packaging cell lines that tested positive for expression of the a or (31 heregulin-gp7O chimeric envelope genes. As the packaging cell lines were selected and maintained in hygromycin, 24 hr after transfection the medium was changed to regular DMEM without hygromycin in preparation for harvesting of virus. Three days after transfection, the supernatant medium was collected, filtered through 0.2-p.m syringe-top filters, and immediately added to the culture medium of the target cells for infection. The target cells, consisting of NIH 3T3 cells or various human breast cancer cell lines, were plated out 24 hr in advance at 60% confluency in 25-cm2 flasks with 5 ml of medium. One millimeter of the same batch of filtered retrovirus-containing medium from each individual packaging cell line was used to infect these target cells simultaneously. Three days after infection, the medium on the target cells was changed to DMEM containing 400 ,ug of G418 per ml for selection, and the medium was changed every 3 days thereafter. Twenty days later, retroviral infection was evaluated by staining with X-Gal, and titers were determined by staining with Giemsa and counting the number of neomycin-resistant colonies.
Stable virus producer cell lines were created by prior transient transfection of PA317 with pCRIP-SVlac or pBAG by calcium phosphate precipitation, and the transiently produced amphotropic virus was harvested 48 hr later as described above and used for infection of the ecotropic packaging cell lines expressing a or (1 heregulin/gp7O chimeric envelope. Infected packaging cells were selected in medium containing 400 ,ug of G418 per ml for 14 days, and neomycin-resistant colonies were isolated and grown in individual wells. High titer-producer cells were identified by infection of NIH 3T3 and human breast cancer cells as described above except that 100 p.l of overnight culture medium without neomycin or hygromycin was harvested and filtered from the producer cells for infection of each flask of target cells.
X-Gal and Giemsa Staining. For X-Gal staining, the cells were fixed in a solution containing 1% glutaraldehyde, 0.1 M sodium phosphate buffer (pH 7.0), and 1 mM MgCl2 for 15 min and then stained with a solution containing 0.2% X-Gal, 10 mM sodium phosphate buffer (pH 7.0), 150 mM NaCl, 1 mM MgCl2, 3.3 mM K4Fe(CN)6, and 3.3 mM K3Fe(CN)6 for 1 hr at 37°C or room temperature overnight. The X-Gal solution was removed, and 70% glycerol was added to the flasks (19) . Pictures were taken under inverted light microscope (x 100 magnification). For Giemsa staining, flasks were washed with phosphate-buffered saline, cells were fixed in acetone/ methanol, T:1 (vol/vol), for 15 min, and 1 ml of Giemsa solution (BDH) was added for 2 min, followed by addition of 5 ml of H20, mixing, and incubation for 2 min, after which the flasks were washed with H20 and dried and the number of colonies were counted. pressing the a or (31 heregulin-gp7O envelope chimeras were used to infect the human breast cancer cell line MDA-MB-453, which overexpresses HER-2 and HER-4 at levels of about 60-fold that of normal human fibroblasts and human mammary epithelial cells (11, 18) , and the human breast cancer cell line MDA-MB-231, which shows undetectable levels of HER-2 and HER-4. CRIP-SVlac or BAG-containing retroviruses produced by wild-type qi-2 cells were used as negative control viruses. All virus preparations were also titered on NIH 3T3 cells, both as a positive control for infection and to ensure that an adequate transfection efficiency had been achieved in each experiment. The infected cells were selected in medium with G418 at 400 ,ag/ml for 3 weeks, and the surviving colonies were stained for (-gal activity. As expected, the ecotropic virus-based vectors produced from all three packaging cell lines infected NIH 3T3 mouse fibroblasts at titers ranging from 104 to 105 per ml. Also as expected, the wild-type ecotropic virus vector produced by the wild-type 4v-2 packaging cell controls could not infect either human breast cancer cell line. However, the ecotropic-based virus vectors produced by packaging cells expressing the heregulin-gp7O chimeric envelopes were able to cross species and to infect the human breast cancer cell line MDA-MB-453, which expresses high levels of both HER-2 and HER-4. In contrast, the human breast cancer cell line MDA-MB-231, which does not express either receptor at detectable levels, remained resistant to infection by these vectors and showed no surviving colonies after G418 selection despite an adequate viral titer as determined by NIH 3T3 cell infections (Fig. 2) . The same results were obtained whether the virus vectors were produced by packaging cells expressing the a or (31 heregulin-gp7O chimeric envelope. The titer of these viruses, produced by transient transfection of packaging cell lines a-17 or ,B1-38, was on the order of 1 x 103 cfu/ml when they were used to infect MDA-MB-453 cells, -1 log below the titer when assayed on NIH 3T3 cells. These results suggest that viruses pseudotyped by heregulin-gp7O chimeric envelopes show specific infectivity for certain human breast cancer cell lines that express high levels of HER-2 and HER-4. In fact, the newly acquired host range of the virus vectors produced by the transfected packaging cell lines shows good correlation with the known binding activity of heregulin itself. That is, cross-species infection was observed in human breast cancer cell lines that express high levels of both HER-2 and HER-4 but was not observed in cell lines that show undetectable levels. It is interesting to note that, although heregulin is known to bind to HER-4 homodimers, cross-species infection was not seen with the MCF-7 cell line, which does not express HER-2 but does express HER-4, albeit at very low levels. It is possible either that the binding affinity of the heregulin ligand for HER-4 homodimers is reduced when it is expressed in the context of this fusion protein, or, perhaps as a more likely explanation, that ligand-mediated cross-species infection is dependent on an adequate number of specific receptors being present on the target cell surface, which may not be the case with the MCF-7 cells. The effect of varying ligand affinities, varying the numbers of ligands on the virus surface, and varying the types and numbers of receptors on the target cell surface, as well as other issues pertinent to ligand-mediated targeting of retrovirus vectors, remain to be investigated.
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HER-2 is overexpressed in 20% of breast cancers, and these tumors are usually more resistant to chemotherapy and more prone to recur (21) . HER-4 is overexpressed in 40% of human breast cancer cell lines and in most cases is coexpressed with HER-2 (11) . In normal breast tissue or benign breast diseases, only very weak immunoreactive HER-2 signals are occasionally seen in the cytoplasm of the epithelial, myoepithelial, and vascular smooth muscle cells, in contrast to the intense immunoreactive HER-2 signals seen on the cell surface of breast cancer epithelium (22, 23) . With regard to clinical applications, it may be unlikely that this type of vector could be administered systemically by the intravenous route in the near future, largely because of problems such as inadequacy of virus titers and rapid inactivation by serum complement; however, we believe it serves as a useful model system to test the feasibility of targeted gene transfer in cancer therapy, and several potential in vivo applications of cell-specific retroviral vectors can be proposed. For example, a cancer-specific virus could be directly injected into tumors for cell-specific delivery of the herpes thymidine kinase gene or cytokine genes to kill the tumor cells with ganciclovir treatment or to induce a cytotoxic T-cell response to the tumor cells. A more practical approach might be to introduce such vectors into the mastectomy site to infect residual tumor cells following surgery. If such procedures are feasible, tumor cell-specific virus vectors may serve as a useful adjunct to radiotherapy and chemotherapy in the treatment of breast cancer.
